Long-term follow-up using a higher target range for lamotrigine monitoring.
The aims of the study were (1) to review the clinical application of the higher target plasma lamotrigine (LTG) concentration of 3-14 mg/L previously proposed by our therapeutic drug monitoring (TDM) laboratory following our initial study 7 years earlier, and (2) to survey clinical application of LTG assays by experienced neurologists (n = 11) who frequently use LTG. There was a 2.9-fold increase in LTG assay requests received by our laboratory from 1996 to 2003. By comparison, data for the number of LTG prescriptions filled throughout Australia were limited to the 4 years from 1997 to 2000, where a 1.7-fold increase was seen. LTG assay requests increased 1.5-fold in this same 4-year period (r2 = 0.97), indicating that the growth in assay requests paralleled the growth in prescriptions. The distribution of LTG concentrations measured in 2003 was compared with those for 1996 and 1997. This indicated there was a significantly increased (P < 0.01) clinical usage of the higher LTG target range. This result was reinforced by questionnaire responses. Respondents (100% of those surveyed), (1) considered the target LTG concentration (3-14 mg/L) to be one of the primary parameters applied in individualizing LTG dosage regimens, (2) were using target concentrations above 7 mg/L in 75% of patients, and (3) reported dose-limiting toxicities in some (but not all) patients typically at concentrations above, or well above, 13 mg/L. In conclusion, the growth in LTG assay requests received by our laboratory paralleled prescribing of this drug. The clinical use of the higher LTG target concentration range was increased during the 7 years since its introduction, indicating clinical acceptance and therapeutic benefit as well as the absence of long-term adverse effects associated with higher plasma LTG concentrations.
Morris
Raymond G
RG
Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia.
Lee
Michelle Y Y
MY
Cleanthous
Xenia
X
Black
Andrew B
AB
D016009:Chi-Square Distribution; D016903:Drug Monitoring / Q000379:methods* / Q000639:trends*; D005500:Follow-Up Studies; D006801:Humans; D000077213:Lamotrigine; D011795:Surveys and Questionnaires; D013997:Time Factors; D014227:Triazines / Q000097:blood*
D014227:Triazines; D000077213:Lamotrigine